The FDA is exploring ways it can regulate CBD in foods and supplements, the Wall Street Journal reports. “The FDA has approved a drug named Epidiolex containing CBD for the treatment of certain types of epilepsy in patients 2 years of age and older,” the reporter writes. “When that drug was being tested, some people taking it had sleeplessness or diarrhea, while others had liver problems that forced them to stop taking it, according to the NIH.… After weighing the evidence, the FDA will decide within months how legal cannabis should best be regulated and whether that will require new agency rules or new legislation from Congress, agency officials said.”
Other FDA-related articles in recent Wall Street Journal articles cover long-standing pressure from pharmacists and other health professionals to remove products containing phenylephrine from the market; revisions to the label for Plan B cautioning against using the product for abortions; and fast-tracking a shift of some formulations of the opioid-reversal agent naloxone to OTC status.